DiaMedica Therapeutics Inc(NASDAQ:DMAC) 
DiaMedica Therapeutics Inc., a clinical stage biopharmaceutical company, develops treatments for neurological and kidney diseases. Its lead drug candidate is DM199, a recombinant human tissue kallikrein-1 protein, which has completed Phase Ib clinical trials for the treatment of patients with modera...
Website: http://www.diamedica.com
Founded: 2000
Full Time Employees: 8
Sector: Healthcare
Industry: Biotechnology
The information provided in this report is taken from www.sec.gov. While we have conducted our best efforts to ensure that the parsed data is accurate, we cannot guarantee its accuracy. Please use caution and understand that any consequences of its use are your own responsibility.
Day
Week
Month
Date 2025-04-04
P
O 3.57
H 3.67
L 3.32
C 3.50
V 117,358
10EMA 3.50
20EMA 3.50
60EMA 3.50
120EMA 3.50
250EMA 3.50